Kweichow Moutai Presents Chinese Enterprise’s ESG Insights at 2025 WEF
Wang Li, General Manager of Kweichow Moutai Group, China's top liquor company, was invited to participate in the 2025 World Economic Forum (WEF) Annual Meeting, which officially opened recently, and shared the Moutai solutions on topics such as ESG practices, green and low-carbon development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124612942/en/
Wang Li, General Manager of Kweichow Moutai Group, presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon. (Photo: Business Wire)
At the 2025 Davos-Tencent Finance Vision Dinner, Wang explained the ESG development based on Moutai's practices. She said that Moutai adheres to long-termism and high-quality development, integrates the ESG concept into the entire production and operation process. By pursuing sustainable development from three dimensions: harmonious coexistence with nature, sharing of social value, and modernization of self-governance, Moutai accumulates momentum and advantages for future development.
Besides, Wang Li presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon as well. She said that Moutai liquor is the result of adhering to harmonious coexistence between mankind and nature. Kweichow Moutai Group insists on leveraging the innovative power of green technology to support the company's green development, focusing on "energy saving, carbon reduction, emission reduction, and efficiency improvement" to achieve "greening level improvement of the main value chain".
Through the resource utilization, greening and high-end development of the by-products in the liquor industry, Moutai has realized the utilization of its by-products. Looking to the future, Moutai will be committed to applying more innovative power and methods of green technology to maintain the characteristics of its products.
Furthermore, Wang proposed Moutai's carbon reduction solution at the First Movers Coalition Leadership Meeting. Wang said, “The accurate management of the whole chain is an important feature of Moutai's carbon emission management. Moutai accounts for the carbon footprint of the whole life cycle of its products and has formulated targeted programs for the transformation of the energy structure, the reduction and greening of packaging materials, etc.”
Moutai also pays attention to the recycling of post-drinking packages, and plans to start post-drinking package recycling in China's provincial capitals in 2025, with the goal of reducing the carbon emissions of the whole industrial chain by 20% by 2030.
During the WEF, Wang Li will also take part in the “China Night” dialogue, sharing Moutai's wisdom with Chinese and foreign experts on the thinking of Chinese enterprises in coping with the age of intelligence and the shaping of the international image of Chinese enterprises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124612942/en/
Contacts
Eason Zhou
Email: evisionsinfo@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom